Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 4/20 | 0.40 |
| ▸ | RARG | P13631 | 3/20 | 0.40 |
| ▸ | RARA | P10276 | 3/20 | 0.40 |
| ▸ | RXRA | P19793 | 2/20 | 0.35 |
| ▸ | HNF4A | P41235 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 6/20 | 0.34 |
| ▸ | DRD3 | P35462 | 5/20 | 0.34 |
| ▸ | DRD4 | P21917 | 2/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | DRD5 | P21918 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1406438 | 0.78 | HNF4A (0.32) | RARBRARGRARARXRAHNF4A | |
| SCHEMBL1406267 | 0.77 | RXRA (0.37) | RARBRARGRARARXRAHNF4A | |
| SCHEMBL8345661 | 0.72 | RARG (0.60) | RARBRARGRARARXRA | |
| SCHEMBL6347726 | 0.70 | RARB (0.49) | RARBRARGRARARXRAHNF4A | |
| SCHEMBL15998741 | 0.70 | HTT (0.39) | PTPN1 | |
| SCHEMBL7478726 | 0.70 | RARB (0.56) | RARBRARGRARARXRAHNF4A | |
| SCHEMBL6348359 | 0.70 | RARB (0.46) | RARBRARGRARARXRAHNF4A | |
| SCHEMBL26498632 | 0.70 | ADORA2A (0.47) | DRD2DRD3PTPN1 | |
| SCHEMBL26498753 | 0.70 | ADORA2A (0.47) | DRD2DRD3PTPN1 | |
| SCHEMBL26498833 | 0.70 | ADORA2A (0.47) | DRD2DRD3PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6849658-B2 | Biaromatic compounds and pharmaceutical and cosmetic compositions comprising them | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2005-02-01 | — | — | US | disclosed |
| US-20030216586-A1 | Biaromatic compounds and pharmaceutical and cosmetic compositions comprising them | GALDERMA RESEARCH & DEVELOPMENT | 2003-11-20 | — | — | US | disclosed |
| US-6346546-B1 | COMPOUNDS HAVING MARKED ACTIVITY IN FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION; TREATING SKIN DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2002-02-12 | — | — | US | disclosed |
| US-6103762-A | A BIAROMATIC COMPOUNDS IN WHICH THE AROMATIC NUCLEI ARE CONNECTED BY A PROPYNYLENE OR ALLENYLENE DIVALENT RADICAL, USEFUL AS HUMAN OR VETERINARY MEDICINE OR USED IN COSMETICS OR KERATINIZATION DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2000-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216586-A1 | Biaromatic compounds and pharmaceutical and cosmetic compositions comprising them | AR, SRR, MC3R | RARB 120/4885RARG 136/4885RARA 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.